GENI Q2 Review: What the Screener Found, and What the Business Proved
GENI
Constructive — the gate is GAAP, not the platform
Since publish GENI +0.0%
GENI: $7.59 → $7.59
as of 2026-08-08
The full review lives at /deep-dives/geni-q2-review/.
This is the post-earnings follow-up to the 25 June thesis, published at $5.83. Q2 2026 reported 6 August: revenue $195.5M against a $185M guide, adjusted EBITDA $52.6M against $45M, and full-year guidance raised on both lines.
Five tabs: the scorecard of what was called against what printed, the Legend revenue back-out, the GAAP-positivity gate that keeps the multiple suppressed, a valuation of the Polymarket and Kalshi agreements, and the revised price target.
deep dives
New deep dives, when they publish
One email per deep dive. Nothing else.
No spam. Unsubscribe anytime.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.